The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

Evercore ISI initiated coverage of Immunome (IMNM) with an Outperform rating and $18 price target The company is developing a deep ADC pipeline ...

Ogsiveo ™ met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease ...

The Food and Drug Administration (FDA) has approved Ogsiveo ™ (nirogacestat) for adult patients with progressing desmoid tumors who require systematic treatment. Desmoid tumors, also known as ...

Confirmed objective response rate (ORR) based on RECIST v1.1 was 41% with Ogsiveo vs. 8% with placebo (p<0.001); the complete response rate was 7% in the Ogsiveo arm and 0% in the placebo arm.